Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 478

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 478
---
. in Law from Bar -IlanUniversity, Israel. Alexander Zwyer, Director Alexander Zwyerhas served as NLS’s Chief Executive Officer and as a Director since NLS’s incorporation in August 2015. Mr. Zwyer has over 25 years of international business experience. In 2007, prior to, and until founding NLS in 2015, Mr. Zwyer founded a start -upin the high -endluxury food sector and served as its chief executive officer until 2015 when he successfully sold the company. From 1991 and until 2007, Mr. Zwyer served in various positions with Viforpharma AG (SWX: VIFN) (then known as Vifor (International) Inc.), most notably serving as Executive Vice President (chief operating officer), leading the company’s global regulatory affairs, medical affairs, sales and marketing as well as business development teams. Mr. Zwyer speaks seven languages fluently. Mr. Zwyer holds a B.B.A. in business administration from Oekral, Zurich, Switzerland and an executive M.B.A. from GSBA/Lorange Institute of Business, Zurich, Switzerland and an M.B.A. from University at Albany SUNY. Tammy Galili, Director Ms. Tammy Galili has served as a director at Kadimastem since July 2021. Ms. Galili has three decades of experience in various management positions in the pharmaceutical space. Ms. Galili served as the CEO of Ilex Medical Ltd. from January 2016 to October 2024, and she previously served as the company’s Deputy CEO in January 2014, and Vice President of Sales and Marketing from January 2010 to December 2013. Ms. Galili has an MBA in Healthcare Innovation from Reichman University, Herzliya, Israel, and a B.A. in Philosophy and History of the Middle East in Modern Times from Tel Aviv University, Israel. Family Relationships Mr.Ariel Revel, Director of Medical Affairs of the combined company, is the son of Professor Michel Revel, Chief Scientific Officer and director of the combined company. Director Independence Mr.Olivier Samuel, Mr.Eran Iohan and Ms. Liora Oren are the independent directors of Kadimastem. The Kadimastem Board has determined that all of its current independent directors are independent, as determined in accordance with the rules of The Nasdaq Stock Market. Mr.Olivier Samuel, Mr